Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey; TRACER Investigators; Peer Grande; Søren Galatius

doi:10.1056/NEJMoa1109719

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

Pierluigi Tricoci, Zhen Huang, Claes Held, David J Moliterno, Paul W Armstrong, Frans Van de Werf, Harvey D White, Philip E Aylward, Lars Wallentin, Edmond Chen, Yuliya Lokhnygina, Jinglan Pei, Sergio Leonardi, Tyrus L Rorick, Ann M Kilian, Lisa H K Jennings, Giuseppe Ambrosio, Christoph Bode, Angel Cequier, Jan H CornelRafael Diaz, Aycan Erkan, Kurt Huber, Michael P Hudson, Lixin Jiang, J Wouter Jukema, Basil S Lewis, A Michael Lincoff, Gilles Montalescot, José Carlos Nicolau, Hisao Ogawa, Matthias Pfisterer, Juan Carlos Prieto, Witold Ruzyllo, Peter R Sinnaeve, Robert F Storey, Marco Valgimigli, David J Whellan, Petr Widimsky, John Strony, Robert A Harrington, Kenneth W Mahaffey, TRACER Investigators, Peer Grande, Søren Galatius

696 Citationer (Scopus)

Abstract

Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.

Originalsprog	Engelsk
Tidsskrift	New England Journal of Medicine
Vol/bind	366
Udgave nummer	1
Sider (fra-til)	20-33
Antal sider	14
ISSN	0028-4793
DOI	https://doi.org/10.1056/NEJMoa1109719
Status	Udgivet - 2012

Adgang til dokumentet

10.1056/NEJMoa1109719

Citationsformater

Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., Van de Werf, F., White, H. D., Aylward, P. E., Wallentin, L., Chen, E., Lokhnygina, Y., Pei, J., Leonardi, S., Rorick, T. L., Kilian, A. M., Jennings, L. H. K., Ambrosio, G., Bode, C., Cequier, A., ... Galatius, S. (2012). Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. New England Journal of Medicine, 366(1), 20-33. https://doi.org/10.1056/NEJMoa1109719

Tricoci, P, Huang, Z, Held, C, Moliterno, DJ, Armstrong, PW, Van de Werf, F, White, HD, Aylward, PE, Wallentin, L, Chen, E, Lokhnygina, Y, Pei, J, Leonardi, S, Rorick, TL, Kilian, AM, Jennings, LHK, Ambrosio, G, Bode, C, Cequier, A, Cornel, JH, Diaz, R, Erkan, A, Huber, K, Hudson, MP, Jiang, L, Jukema, JW, Lewis, BS, Lincoff, AM, Montalescot, G, Nicolau, JC, Ogawa, H, Pfisterer, M, Prieto, JC, Ruzyllo, W, Sinnaeve, PR, Storey, RF, Valgimigli, M, Whellan, DJ, Widimsky, P, Strony, J, Harrington, RA, Mahaffey, KW, TRACER Investigators, Grande, P & Galatius, S 2012, 'Thrombin-receptor antagonist vorapaxar in acute coronary syndromes', New England Journal of Medicine, bind 366, nr. 1, s. 20-33. https://doi.org/10.1056/NEJMoa1109719

@article{541fb697d796422eb0d69846383682ff,

title = "Thrombin-receptor antagonist vorapaxar in acute coronary syndromes",

abstract = "Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.",

keywords = "Acute Coronary Syndrome, Aged, Angioplasty, Cardiovascular Diseases, Combined Modality Therapy, Coronary Artery Bypass, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage, Humans, Intracranial Hemorrhages, Kaplan-Meier Estimate, Lactones, Male, Middle Aged, Platelet Aggregation Inhibitors, Pyridines, Receptor, PAR-1",

author = "Pierluigi Tricoci and Zhen Huang and Claes Held and Moliterno, {David J} and Armstrong, {Paul W} and {Van de Werf}, Frans and White, {Harvey D} and Aylward, {Philip E} and Lars Wallentin and Edmond Chen and Yuliya Lokhnygina and Jinglan Pei and Sergio Leonardi and Rorick, {Tyrus L} and Kilian, {Ann M} and Jennings, {Lisa H K} and Giuseppe Ambrosio and Christoph Bode and Angel Cequier and Cornel, {Jan H} and Rafael Diaz and Aycan Erkan and Kurt Huber and Hudson, {Michael P} and Lixin Jiang and Jukema, {J Wouter} and Lewis, {Basil S} and Lincoff, {A Michael} and Gilles Montalescot and Nicolau, {Jos{\'e} Carlos} and Hisao Ogawa and Matthias Pfisterer and Prieto, {Juan Carlos} and Witold Ruzyllo and Sinnaeve, {Peter R} and Storey, {Robert F} and Marco Valgimigli and Whellan, {David J} and Petr Widimsky and John Strony and Harrington, {Robert A} and Mahaffey, {Kenneth W} and {TRACER Investigators} and Peer Grande and S{\o}ren Galatius",

year = "2012",

doi = "10.1056/NEJMoa1109719",

language = "English",

volume = "366",

pages = "20--33",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "1",

}

TY - JOUR

T1 - Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

AU - Tricoci, Pierluigi

AU - Huang, Zhen

AU - Held, Claes

AU - Moliterno, David J

AU - Armstrong, Paul W

AU - Van de Werf, Frans

AU - White, Harvey D

AU - Aylward, Philip E

AU - Wallentin, Lars

AU - Chen, Edmond

AU - Lokhnygina, Yuliya

AU - Pei, Jinglan

AU - Leonardi, Sergio

AU - Rorick, Tyrus L

AU - Kilian, Ann M

AU - Jennings, Lisa H K

AU - Ambrosio, Giuseppe

AU - Bode, Christoph

AU - Cequier, Angel

AU - Cornel, Jan H

AU - Diaz, Rafael

AU - Erkan, Aycan

AU - Huber, Kurt

AU - Hudson, Michael P

AU - Jiang, Lixin

AU - Jukema, J Wouter

AU - Lewis, Basil S

AU - Lincoff, A Michael

AU - Montalescot, Gilles

AU - Nicolau, José Carlos

AU - Ogawa, Hisao

AU - Pfisterer, Matthias

AU - Prieto, Juan Carlos

AU - Ruzyllo, Witold

AU - Sinnaeve, Peter R

AU - Storey, Robert F

AU - Valgimigli, Marco

AU - Whellan, David J

AU - Widimsky, Petr

AU - Strony, John

AU - Harrington, Robert A

AU - Mahaffey, Kenneth W

AU - TRACER Investigators

AU - Grande, Peer

AU - Galatius, Søren

PY - 2012

Y1 - 2012

N2 - Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.

AB - Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.

KW - Acute Coronary Syndrome

KW - Aged

KW - Angioplasty

KW - Cardiovascular Diseases

KW - Combined Modality Therapy

KW - Coronary Artery Bypass

KW - Double-Blind Method

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Hemorrhage

KW - Humans

KW - Intracranial Hemorrhages

KW - Kaplan-Meier Estimate

KW - Lactones

KW - Male

KW - Middle Aged

KW - Platelet Aggregation Inhibitors

KW - Pyridines

KW - Receptor, PAR-1

U2 - 10.1056/NEJMoa1109719

DO - 10.1056/NEJMoa1109719

M3 - Journal article

C2 - 22077816

SN - 0028-4793

VL - 366

SP - 20

EP - 33

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 1

ER -

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater